Page 25 - Pharma Companies

US drag on pharma majors' margins in Q4; experts see R&D costs rising

While the US headwinds continue, domestic market sales have been positive and show signs of recovery after the implementation of the goods and services tax

From Cipla to Glenmark, pharma companies' double-digit growth in doubt

Govt's proposed changes in pricing policy could play spoilsport

Eight Chinese pharma firms may get blacklisted over low quality materials

The notices were issued after a special inspection team of the Drug Controller General of India inspected the eight companies in China

Pharma companies' revenues seen growing at 9% over next 3 years: Crisil

Exports, which account for nearly 45 per cent of industry revenue, will see another year of a tepid one per cent growth in fiscal 2018

Revival of US generic sales not before FY19, say analysts

Sharp fall in Teva's June quarter earnings dash hopes of recovery for domestic pharma firms

Pharma companies may report subdued performance in Q2 FY17: Report

The US remains mainstay for most companies, contributing 55-60 per cent of total exports

Pharma companies' profits will moderate in near term: CRISIL

According to CRISIL, exports of generic drugs to the US will slow down 300 basis points to 10-12% in the medium term

Earnings support expected for pharma

This will be a relief for the sector, which is battling regulatory pressures at home and in the US